​

Day One Biopharmaceuticals (DAWN) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Day One Biopharmaceuticals Revenue Highlights

Latest Revenue (Y)

$131.16M

Latest Revenue (Q)

$33.91M

Main Segment (Y)

License

Day One Biopharmaceuticals Revenue by Period

Day One Biopharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31$131.16M100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--

Day One Biopharmaceuticals generated $131.16M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Day One Biopharmaceuticals Revenue by Quarter

DateRevenueChange
2025-06-30$33.91M10.23%
2025-03-31$30.76M5.32%
2024-12-31$29.21M-68.85%
2024-09-30$93.76M1044.54%
2024-06-30$8.19M100.00%
2024-03-31--100.00%
2023-12-31$560.00K100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

Day One Biopharmaceuticals generated $33.91M in revenue during Q2 2025, up 10.23% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Day One Biopharmaceuticals Revenue Breakdown

Day One Biopharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
License$73.94M
Product$57.22M

Day One Biopharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (56.38%), and Product (43.62%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25Dec 24Sep 24Jun 24
License$346.00K$258.00K$253.00K$73.69M-
Product$33.56M$30.50M$28.95M$20.07M$8.19M

Day One Biopharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Product (98.98%), and License (1.02%).

Day One Biopharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ARVNArvinas$263.40M$22.40M
AKBAAkebia Therapeutics$160.18M$57.34M
DAWNDay One Biopharmaceuticals$131.16M$33.91M
URGNUroGen Pharma$90.40M$20.25M
GERNGeron$76.50M$49.04M
NRIXNurix Therapeutics$54.55M$7.89M
RZLTRezolute--
OLMAOlema Pharmaceuticals--
TERNTerns Pharmaceuticals--
ERASErasca--
TYRATyra Biosciences--

DAWN Revenue FAQ

What is Day One Biopharmaceuticals’s yearly revenue?

Day One Biopharmaceuticals's yearly revenue for 2024 was $131.16M, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. DAWN's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is Day One Biopharmaceuticals’s quarterly revenue?

Day One Biopharmaceuticals's quarterly revenue for Q2 2025 was $33.91M, a 10.23% increase from the previous quarter (Q1 2025), and a 313.92% increase year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $30.76M, a 5.32% increase from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024). DAWN's quarterly revenue for Q4 2024 was $29.21M, a -68.85% decrease from the previous quarter (Q3 2024), and a 5115.71% increase year-over-year (Q4 2023).

What is Day One Biopharmaceuticals’s revenue growth rate?

Day One Biopharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.

What are Day One Biopharmaceuticals’s revenue streams?

Day One Biopharmaceuticals's revenue streams in c 24 are License, and Product. License generated $73.94M in revenue, accounting 56.38% of the company's total revenue Product generated $57.22M in revenue, accounting 43.62% of the company's total revenue

What is Day One Biopharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Day One Biopharmaceuticals was License. This segment made a revenue of $73.94M, representing 56.38% of the company's total revenue.